DESTINY-Breast03 Phase 3 Study Results

• · Case Summary: Patient With Serous OVC 67-year-old woman with stage IV platinum-resistant OVC Treated with DS-6000a 6.4 mg/kg intravenously q3w 3 prior therapies • . • Paclitaxel + carboplatin with olaparib maintenance Carboplatin + gemcitabine + bevacizumab Pegylated liposomal doxorubicin Cycle 14 treatment ongoing Baseline 18 weeks Overall SD (-26.2%) 36 weeks Overall PR (-35.7%) OVC, ovarian cancer; PR, partial response; q3w, every 3 weeks; SD, stable disease. ASCO 2022 #3002 Oral Daiichi-Sankyo 106

View entire presentation